Risk factors affecting pancreatic fistulas after pancreaticoduodenectomy

Yun-Mee Choe, Keon-Young Lee, Cheong-Ah Oh, Joung-Bum Lee, Sun Keun Choi, Yoon-Seok Hur, Sei-Joong Kim, Young Up Cho, Seung-Ik Ahn, Kee-Chun Hong, Seok-Hwan Shin, Kyung-Rae Kim

© 2008 The WJG Press. All rights reserved.

Key words: Pancreaticoduodenectomy; Pancreatic fistula; Pancreatic leakage

Peer reviewer: Justin H Nguyen, MD, Division of Transplant Surgery, Mayo Clinic, 4205 Belfort Road, Suite 1100, Jacksonville, Florida 32256, United States

Abstract

AIM: To analyze the risk factors of pancreatic leakage after pancreaticoduodenectomy.

METHODS: We retrospectively reviewed 172 consecutive patients who had undergone pancreaticoduodenectomy at Inha University Hospital between April 1996 and March 2006. We analyzed the pancreatic fistula rate according to the clinical characteristics, the pathologic and laboratory findings, and the anastomotic methods.

RESULTS: The incidence of developing pancreatic fistulas in patients older than 60 years of age was 21.7% (25/115), while the incidence was 8.8% (5/57) for younger patients; the difference was significant ($P = 0.03$). Patients with a dilated pancreatic duct had a lower rate of post-operative pancreatic fistulas than patients with a non-dilated duct ($P = 0.001$). Other factors, including clinical features, anastomotic methods, and pathologic diagnosis, did not show any statistical difference.

CONCLUSION: Our study demonstrated that pancreatic fistulas are related to age and a dilated pancreatic duct. The surgeon must take these risk factors into consideration when performing a pancreaticoduodenectomy.

INTRODUCTION

Pancreaticoduodenectomy (PD) is a commonly performed surgical procedure for managing duodenal trauma and various benign and malignant diseases of the periampullary region.

This procedure was first described by Whipple et al. in 1935. At that time, PD was technically difficult to perform and the mortality rate was reported to be > 30% [1]. Despite marked progress in the procedure and in the treatment of perioperative patients, the mortality rate is still reported to be 2%-10% in most hospitals [2,3]. The incidence of pancreatic fistulas remains a major cause of postoperative complications; it is reported that the incidence of pancreatic fistulas after PD is 6%-25% [4-12]. It is known that such pancreatic fistulas induce abscess formation, vascular injuries, rupture of pseudoaneurysms, and postoperative delayed hemorrhage, all resulting from inflammation around leakage sites due to stasis of fluid, including active pancreatic enzymes [13-16].

The aim of this study was to analyze the independent risk factors for pancreatic fistulas after PD.

MATERIALS AND METHODS

Between April 1996 and March 2006, 172 consecutive patients who had undergone PD at Inha University Hospital were retrospectively reviewed. The operations were performed by five surgeons, and pancreatic fistulas were investigated retrospectively by review of the patients’
medical records. A pancreatic fistula was defined as follows: from the 7th postoperative day on, the drainage output was > 50 cc a day and the drainage fluid amylase level was 3 times higher than the serum level.[8]

We compared the pancreatic fistula rates based on gender, age, anastomotic method, preoperative serum total bilirubin level, serum albumin level, white blood cell (WBC) count, histologic diagnosis, texture of the remnant pancreas, and size of the pancreatic duct. The methods used for anastomosis included end-to-end anastomosis (dunking) between cross-sections of the jejunum and the pancreatic stump, and a pancreatic duct-to-jejunal mucosal anastomosis. The results were compared based on whether or not a feeding tube was placed into the duct, serving as a stent for the reconstruction and exteriorization of the duct from the anastomotic site through the lateral abdominal wall.

In all cases, somatostatin was used prophylactically for 7 d postoperatively. The statistical analyses of the correlations among multiple clinical factors were performed using independent t-tests and \( \chi^2 \) tests, and a significant difference was considered when \( P < 0.05 \). The assessment of the statistical significance was carried out using multivariate analyses.

RESULTS

Leakage of the pancreaticojejunostomy occurred in 30 of 172 patients (17.4%), and the frequency of such leakage was analyzed and compared according to gender, age, anastomotic methods, operative findings, preoperative serum total bilirubin and albumin levels, preoperative WBC, and histopathologic diagnosis (Table 1).

Reoperations were carried out in 5 of 30 patients (16.7%) with leakage of the pancreaticojejunostomy; 4 patients had total pancreatectomies and 1 patient had a segmental resection of the small bowel. Among 172 patients, there were 4 deaths and the mortality rate was 2.3%; 1 patient underwent reoperation and 3 patients died during conservative management. There were 4 deaths in groups with leakage of the pancreaticojejunostomy.

Five surgeons operated on 95, 26, 19, 19, and 13 patients, respectively, in our hospital. The occurrences of pancreatic fistulas according to the surgeons were 17.9% (17/95), 23.1% (6/26), 15.8% (3/19), 10.5% (2/19), and 15.4% (2/13), respectively. There was no significant correlation between the surgeons and pancreatic fistulas (\( P = 0.867 \)).

The mean age of the patients was 62.2 years, with a range of 33-87 years. Pancreatic fistulas occurred in 25 patients over 60 years of age (21.7%), and in 5 of 57 patients under 60 years of age (8.8%). The difference in the pancreatic fistula rates between the two groups was significant (\( P = 0.016 \)).

With regard to gender, anastomotic method, pancreatic stenting, texture of the remnant pancreas, preoperative serum albumin level, total bilirubin level, and WBC count, there were no significant differences in pancreatic fistula rates.

The pancreatic duct size was included in the pathology reports and the patients were divided into 2 groups based on the main duct size, as follows: (1) patients with a dilated pancreatic main duct, defined as having a visible main duct and (2) a non-dilated pancreatic main duct, defined as having a non-visible main duct. Only 136 of 172 patients were classified according to pancreatic duct size. The number of patients with dilated and non-dilated pancreatic main ducts was 60 and 76, respectively. Pancreatic fistulas developed in 4 of 60 patients in the group with a dilated pancreatic main duct (6.6%), and in 21 of 76 patients in the group with a non-dilated pancreatic main duct (27.6%); there was a significant difference between the two groups (\( P = 0.001; \) Table 1).

When the incidence of pancreatic fistulas was compared based on histopathologic diagnosis, pancreatic fistulas occurred in 6 of 37 patients (16.2%) diagnosed with carcinomas in the pancreatic head, in 8 of 46 patients (17.4%) diagnosed with carcinomas in the common bile duct (CBD), in 8 of 34 patients (23.5%) diagnosed with carcinomas of the ampulla of Vater, in 1 of 10 patients (10.0%) diagnosed with duodenal cancer, in 3 of 9 patients (33.3%) diagnosed with intraductal papillary mucinous tumors, in 0 of 6 patients (0%) diagnosed with chronic pancreatitis, in 2 of 22 patients (9.1%) diagnosed with gastric cancer and pancreatic invasion, in 1 of 4 patients (25.0%) with trauma to the pancreas, and in 1 of 4 patients (25.0%) diagnosed with gallbladder (GB) cancer (Table 2). Although patients diagnosed with chronic pancreatitis and gastric cancer with pancreatic invasion tended to develop pancreatic fistulas less frequently than other patients, there was no significant difference in the correlation between histopathologic diagnosis and pancreatic fistulas.

Table 1  Pancreatic fistula rate based on clinical factors

| Factors                          | Number of patients (%) | Leakage (%) | \( P \) value |
|---------------------------------|------------------------|-------------|--------------|
| Age (yr)                        |                        |             |              |
| ≥ 60                            | 115 (66.9)             | 25 (21.7)   | 0.016        |
| < 60                            | 57 (32.1)              | 5 (8.8)     |              |
| Gender                          |                        |             |              |
| Male                            | 116 (67.4)             | 19 (16.4)   |              |
| Female                          | 56 (32.6)              | 11 (19.6)   | 0.606        |
| Type of anastomosis             |                        |             |              |
| Duct-to-mucosa                  | 133 (77.3)             | 22 (16.5)   |              |
| End-to-end                      | 39 (22.7)              | 8 (19.6)    | 0.582        |
| Pancreatic stent                 |                        |             |              |
| Yes                             | 58 (33.7)              | 11 (19.0)   | 0.712        |
| No                              | 114 (66.3)             | 19 (16.7)   |              |
| Texture of remnant pancreas     |                        |             |              |
| Hard                            | 61 (58.5)              | 7 (16.3)    | 0.392        |
| Soft                            | 43 (41.5)              | 7 (23.0)    |              |
| Pancreatic duct size            |                        |             |              |
| Dilated                         | 60 (44.1)              | 4 (6.6)     | 0.001        |
| Non-dilated                     | 76 (55.9)              | 21 (27.6)   |              |
| Pre-op bilirubin                | ≥ 1.3 mg/dL            | 15 (16.3)   | 0.674        |
| < 1.3 mg/dL                     | 80 (46.5)              | 15 (18.8)   |              |
| Pre-op albumin                  | ≥ 3.1 g/dL             | 23 (16.7)   | 0.607        |
| < 3.1 g/dL                      | 34 (19.8)              | 7 (20.6)    |              |
| Pre-op WBC                      | ≥ 10000/mm³            | 7 (24.1)    | 0.349        |
| < 10000/mm³                     | 143 (83.1)             | 23 (16.1)   |              |

DISCUSSION

PD is technically difficult, and as a result, relatively high mortality (15%-30%) and complication rates (50%-75%) were reported before the 1980s. With advances in surgi-
clinical techniques and perioperative care, the mortality rate associated with PD has since improved\[17].

Most complications after PD commonly arise from failure in healing of the pancreaticojejunostomy, and have been described as pancreatic fistulas or anastomotic leakages by various authors.

Berberat et al\[16\] defined a pancreatic fistula as an anastomotic leak of the pancreaticojejunostomy demonstrated radiographically or intraoperatively, and as a prolonged or elevated output of amylase-rich fluid through an intraoperatively-placed drain (> 3 times the normal serum amylase level). Lowy et al\[17\] divided pancreatic fistulas into clinical leakage and biochemical leakage, in which the former referred to the amylase level of the fluid obtained through an intraoperatively-placed drain to be > 3 times the normal serum amylase level, with a high fever, leukocytosis, sepsis, and the need for drainage, while the latter referred to asymptomatic patients. We favor the definition described by Yeo et al\[6\] i.e. from the 7th postoperative day on, the drain output is > 50 cc a day and the drain fluid amylase level is 3 times higher than the serum amylase level. Using the Yeo et al\[6\] definition, we analyzed the risk factors for pancreatic leakage.

To place a tube as a stent and to determine how a pancreaticojejunostomy relates to pancreatic fistula formation requires more research\[20\]. Yeo et al\[21\] reported that pancreatic fistulas were correlated with anastomotic technique, operative time, a surgeon's rich fluid and experience in performing a PD, tumor location, and co-morbid illnesses\[20\]. Bartoli et al\[23\] reported a difference in the degree of fibrosis of the remnant pancreas, and that anastomotic leakage occurred in 5% of patients with chronic pancreatitis and in 33% of patients with carcinoma of the CBD. Patients in whom the pancreatic texture has a hard consistency have been reported to be at lower risk for pancreatic leakage than those patients who have a pancreatic parenchyma with a soft or intermediate consistency\[21,22\]. The texture of the pancreatic parenchyma has been reported to be correlated with the pancreatic duct diameter\[24\], in considering the case in performing a pancreatic duct-to-jejunal mucosa anastomosis, such a simple comparison requires more consideration. The pancreatic duct diameter has been correlated with pancreatic leakage\[5\], and our study showed that 136 (79.1%) patients had evidence of pancreatic duct dilatation by histopathologic reports, confirming the correlation between pancreatic duct size and pancreatic fistula development (P = 0.001). None of the 6 patients with chronic pancreatitis developed pancreatic leakage, and chronic pancreatitis induced pancreatic fistula less often than other pancreatic diseases; however, there was no statistical significance. We considered this result to reflect a small number of the population and because of the possible prediction of pancreatic duct dilatation in chronic pancreatitis, pancreatic duct diameter could be correlated with pancreatic leakage. However, in considering factors related to the texture of the remnant pancreas, the incidence of pancreatic fistulas in patients with a hard texture of the remnant pancreatic parenchyma was 16.3% (7/43) and was lower than that in patients with a soft texture [23% (14/61)], but this finding lacked statistical significance (P = 0.392). These results are considered to have no statistical significance because pancreatic texture was demonstrated in only 104 of 172 patients (60.5%).

In this study, the incidence of pancreatic fistulas in patients with gastric cancer with pancreatic invasion was 9.1% and was lower than that in patients with other diseases, again showing no statistical significance. Among 22 patients with gastric cancer with pancreatic invasion, 13 patients were < 60 years of age, suggesting that gastric cancer with pancreatic invasion affects a younger age group when compared with 57 patients < 60 years of age in the total population of 172 patients. These results were considered to be influenced by the bias arising from the difference between the older age group, a significant factor in our study, and the younger age group of patients with gastric cancer with pancreatic invasion.

Pancreatic leakage has been related to the presence or absence of co-morbid illnesses, and age has been correlated with the occurrence of pancreatic fistulas\[21-23\]. In our study, there was a significant correlation between age and pancreatic fistulas (P = 0.03).

With regard to the pancreaticojejunostomy technique, binding pancreaticojejunostomy significantly decreased postoperative complications and the pancreaticojejunostomy leakage rate\[21-23\]. In our study, the methods used for anastomosis were divided into end-to-end dunking anastomosis between cross-sections of the jejunum and the pancreatic stump, and pancreatic duct-to jejunal mucosal anastomosis. The results were compared based on whether or not a feeding tube, which serves as a stent for the reconstruction and exteriorization, was placed from the anastomotic site through the lateral abdominal wall.

Many previous reports have proposed that hard texture of the pancreatic parenchyma and a dilated pancreatic duct have a lower risk of pancreatic fistula formation owing to an ability to prevent pancreatic duct dilatation and shrinkage of the pancreaticojejunostomy after PD\[16\]. Conversely, in the case of a small pancreatic duct and a soft pancreas, an end-to-end invagination anastomosis or binding pancreaticojejunostomy significantly decreases postoperative complications\[20,22\]. In our study there was no significant difference in the incidence of pancreatic fistulas as a function of anastomotic technique.

Table 2 Pancreatic fistula based on histopathologic diagnosis

| Name of disease            | Number of patients (%) | Leakage (%) |
|----------------------------|------------------------|-------------|
| Pancreatic head cancer      | 37 (21.5)              | 6 (16.2)    |
| CBD cancer                 | 46 (26.7)              | 8 (17.4)    |
| Ampulla of Vater cancer    | 34 (19.8)              | 8 (23.5)    |
| Duodenal cancer            | 10 (5.8)               | 1 (10.0)    |
| Chronic pancreatitis       | 6 (3.5)                | 0 (0)       |
| Intraductal papillary mucinous tumor | 34 (19.8) | 9 (5.2)    |
| Gastric cancer             | 22 (12.8)              | 2 (9.1)     |
| GB cancer                  | 4 (2.3)                | 1 (25)      |
| Trauma                     | 4 (2.3)                | 1 (25)      |

\[16\] Lowy et al, \[17\] Yeo et al
Although there is a report that the preoperative serum total bilirubin level, duration of jaundice, surgery performed under emergent conditions, and preoperative serum albumin level can affect the occurrence of pancreatic fistulas, there was no significant difference among the preoperative serum total bilirubin level, albumin level, and leukocytosis in our study. The patients with pancreatic parenchyma of soft consistency produce a larger amount of pancreatic juice and have a higher risk of pancreatic leakage than those with a hard consistency. Therefore, a variety of surgical methods have been attempted. Specifically, efforts to exteriorize the pancreatic fluid with a tube, to place a tube into the pancreatic duct, and to use synthetic somatostatin prophylactically have been attempted, but the reports have failed to show a statistically significant difference among the techniques.

In this study, it was demonstrated that there were no significant differences in the incidence of pancreatic fistulas based on surgical technique. Therefore, we are of the opinion that the surgical technique should be individualized based on the patient’s condition and the surgeon’s preferences.

We demonstrated several risk factors related to pancreatic leakage after PD; age and pancreatic duct size were significantly correlated with an increased incidence of pancreatic fistula. In conclusion, it is important that surgeons are aware of these risk factors for pancreatic fistula formation when performing a PD.

**COMMENTS**

**Background**
Pancreatectoduodenectomy is technically difficult, and as a result, relatively high mortality (15%-30%) and complication rates (50%-75%) were reported before the 1980s. With advances in surgical techniques and perioperative care, the mortality rate associated with PD has since improved.

**Research frontiers**
Most complications after PD commonly arise from failure in healing of the pancreaticojejunostomy, and have been described as pancreatic fistulas or anastomotic leakages by various authors.

**Innovations and breakthroughs**
The incidence of developing pancreatic fistulas in patients older than 60 years of age was 21.7% (25/115), while the incidence was 8.8% (5/57) for younger patients; the difference was significant. The patients with a dilated pancreatic duct had a lower rate of post-operative pancreatic fistulas than the patients with a non-dilated duct.

**Applications**
This study demonstrated that pancreatic fistulas are related to age and a dilated pancreatic duct. The surgeon must take these risk factors into consideration when performing a pancreaticoduodenectomy.

**Peer review**
A well organized paper about the risk factors affecting pancreatic fistulas after pancreaticoduodenectomy.

**REFERENCES**

1. Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of vater. *Ann Surg* 1935; 102: 763-779
2. Marcus SG, Cohen H, Ransohoff JH. Optimal management of the pancreatic remnant after pancreatectoduodenectomy. *Ann Surg* 1995; 221: 635-645; discussion 645-648
3. Bottger TC, Junginger T. Factors influencing morbidity and mortality after pancreatectoduodenectomy: critical analysis of 221 resections. *World J Surg* 1999; 23: 164-171; discussion 171-172
4. Neoptolemos JP, Russell RC, Bramhall S, Theis B. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. UK Pancreatic Cancer Group. *Br J Surg* 1997; 84: 1370-1376
5. Miedema BW, Sarr MG, van Heerden JA, Nagorney DM, McIlrath DC, Istrup D. Complications following pancreatectoduodenectomy. Current management. *Arch Surg* 1992; 127: 945-949; discussion 949-950
6. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB, Abrams RA. Six hundred fifty consecutive pancreatectoduodenectomies in the 1990s: pathology, complications, and outcomes. *Ann Surg* 1997; 226: 248-257; discussion 257-260
7. Rosenberg L, MacNeil P, Turcotte L. Economic evaluation of the use of octreotide for prevention of complications following pancreatic resection. *J Gastrointest Surg* 1999; 3: 225-232
8. Buchler MW, Fries H, Bittner R, Roscher R, Krautzberger W, Muller MW, Malfertheiner P, Beger HG. Duodenum-preserving pancreatic head resection: Long-term results. *J Gastrointest Surg* 1997; 1: 13-19
9. Liebermann MD, Killburn H, Lindsey M, Brennan MF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. *Ann Surg* 1995; 222: 638-645
10. Trede M, Schwall G. The complications of pancreatectomy. *Ann Surg* 1988; 207: 39-47
11. Cullen JJ, Sarr MG, Istrup DM. Pancreatic anastomotic leak after pancreatectoduodenectomy: incidence, significance, and management. *Ann J Surg* 1994; 168: 295-298
12. Strasberg SM, Drebien JA, Soper NJ. Evolution and current status of the Whipple procedure: an update for gastroenterologists. *Gastroenterology* 1997; 113: 983-994
13. Brodsky JT, Turnbull AD. Arterial hemorrhage after pancreatectoduodenectomy. The ‘sentinel bleed’. *Arch Surg* 1991; 126: 1037-1040
14. Hamanaka Y, Nishihiara K, Hamasaki T, Kawabata A, Yamamoto S, Tsurumi M, Ueno T, Suzaki T. Pancreatic juice output after pancreatectoduodenectomy in relation to pancreatic consistency, duct size, and leakage. *Surgery* 1996; 119: 281-287
15. van Berge Henegouwen MI, De Wit LT, Van Gulik TM, Obertop H, Gouma DJ. Incidence, risk factors, and treatment of pancreatic leakage after pancreatectoduodenectomy: drainage versus resection of the pancreatic remnant. *J Am Coll Surg* 1997; 185: 18-24
16. Tani M, Onishi H, Kimoshita H, Kawai M, Ueno M, Hama T, Uchiyama K, Yamane H. The evaluation of duct-to-mucosal pancreaticojejunostomy in pancreatectoduodenectomy. *World J Surg* 2005; 29: 76-79
17. Bartoli FG, Arnone GB, Ravera G, Bachi V. Pancreatic fistula and relative mortality in malignant disease after pancreatectoduodenectomy. *Review and statistical meta-analysis regarding 15 years of literature. Anticancer Res* 1991; 11: 1831-1848
18. Berberat PO, Fries H, Uhl W, Buchler MW. The role of octreotide in the prevention of complications following pancreatic resection. *Digestion* 1999; 60 Suppl 1: 15-22
19. Lowsy AM, Lee JE, Pisters PW, Davidson BS, Fenoglio CJ, Stanford P, Jinnah R, Evans DB. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreatectoduodenectomy. *Ann Surg* 1997; 226: 652-641
20. Poon RT, Lo SH, Feng D, Fan ST, Wong J. Prevention of pancreatic anastomotic leakage after pancreatectoduodenectomy. *Ann Surg* 2002; 183: 42-52
21. Yeo CJ, Cameron JL, Maher MM, Sauter PK, Zahurak
ML, Talamini MA, Lillemoe KD, Pitt HA. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. *Ann Surg* 1995; 222: 580-588; discussion 588-592

22 Reid-Lombardo KM, Farnell MB, Crippa S, Barnett M, Maupin G, Bassi C, Traverso LW. Pancreatic anastomotic leakage after pancreaticoduodenectomy in 1,507 patients: a report from the Pancreatic Anastomotic Leak Study Group. *J Gastrointest Surg* 2007; 11: 1451-1458; discussion 1459

23 Yang YM, Tian XD, Zhuang Y, Wang WM, Wan YL, Huang YT. Risk factors of pancreatic leakage after pancreaticoduodenectomy. *World J Gastroenterol* 2005; 11: 2456-2461

24 Suzuki Y, Fujino Y, Tanioka Y, Hiraoka K, Takada M, Ajiki T, Takeyama Y, Ku Y, Kuroda Y. Selection of pancreaticojejunostomy techniques according to pancreatic texture and duct size. *Arch Surg* 2002; 137: 1044-1047; discussion 1048

25 Peng S, Mou Y, Cai X, Peng C. Binding pancreaticojejuno-

26 Yeo CJ, Cameron JL, Lillemoe KD, Sauter PK, Coleman J, Sohn TA, Campbell KA, Choti MA. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. *Ann Surg* 2000; 232: 419-429

27 Peng SY, Wang JW, Lau WY, Cai XJ, Mou YP, Liu YB, Li JT. Conventional versus binding pancreaticojejunostomy after pancreaticoduodenectomy: a prospective randomized trial. *Ann Surg* 2007; 245: 692-698

28 Billingsley KG, Hur K, Henderson WG, Daley J, Khuri SF, Bell RH Jr. Outcome after pancreaticoduodenectomy for periampullary cancer: an analysis from the Veterans Affairs National Surgical Quality Improvement Program. *J Gastrointest Surg* 2003; 7: 484-491

S- Editor Tian L  L- Editor Webster JR  E- Editor Ma WH